Lectures

Autor: J. Doroshow, E. T. Liu, M. Pellini, V. Miller, G. Palmer, S. Averbuch, G. Green, J. Novotny, P. Paoletti, K. Patel, A. Hoos, R. Gaynor, S. Melemed, C. Reinhard, B. T. Teh, W. K. Hong, E. Kim, R. Herbst, V. Papadimitrakopoulou, K. Gold, I. Wistuba, J. Lee, S. Lippman, J. R. Jackson, L. Zitvogel, C. Meisel, P. Workman, W. S. Dalton, N. Botwood, B. J. Davis, G. Batist, S. Assouline, E. Camlioglu, B. Tetu, A. Spatz, Z. Diaz, A. Aguilar-Mahecha, M. Basik, J. Rodon, R. Dienstmann, J. Cortes, C. Saura, C. Aura, J. Hernandez-Losa, A. Vivancos, J. Joan, J. del Campo, E. Felip, J. Seoane, J. T. Tabernero, S. H. Friend, A. M. Tsimberidou, D. S. Hong, J. J. Wheler, Y. Ye, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock, M. Naley, P. Johnson, K. Schuerer, M. Lopes, L. E. Hood, Y. Yarden, J. Quackenbush

Publikováno v: Annals of Oncology. 23:v6-v11

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ac6a6f741c8c4f76c5b7d74865066bef
https://doi.org/10.1093/annonc/mds160

Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer

Autor: S E, Salmon, W S, Dalton, T M, Grogan, P, Plezia, M, Lehnert, D J, Roe, T P, Miller

Publikováno v: Blood. 78:44-50

Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59 myeloma patients in relapse were evaluated for several resistance parameters: expression of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9f0d74c5e600c5182596e3099cdf3e0
https://doi.org/10.1182/blood.v78.1.44.bloodjournal78144

Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies

Autor: L A, Hazlehurst, W S, Dalton

Publikováno v: Cancer metastasis reviews. 20(1-2)

The tumor microenvironment is often overlooked when considering tumor response to chemotherapeutic agents. This environment consists of soluble factors, components of the extracellular matrix as well as cell-cell interactions. Recently, it has become

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b3114b2ef20c03b3f1eb6c432099a544
https://pubmed.ncbi.nlm.nih.gov/11831646

Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest

Autor: G, Niu, K H, Shain, M, Huang, R, Ravi, A, Bedi, W S, Dalton, R, Jove, H, Yu

Publikováno v: Cancer research. 61(8)

Gene therapy of B16 tumors with a dominant-negative signal transducer and activator of transcription (Stat3) variant, designated Stat3beta, results in inhibition of tumor growth and tumor regression. Although only 10-15% of the tumor cells are transf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::81bd4188a184e633b4e359aa8e0b20e8
https://pubmed.ncbi.nlm.nih.gov/11309279

Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray

Autor: K, Kudoh, M, Ramanna, R, Ravatn, A G, Elkahloun, M L, Bittner, P S, Meltzer, J M, Trent, W S, Dalton, K V, Chin

Publikováno v: Cancer research. 60(15)

Drug resistance in cancer is a major obstacle to successful chemotherapy. Cancer cells exposed to antitumor drugs may be directly induced to express a subset of genes that could confer resistance, thus allowing some cells to escape killing and form t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::aca26950fdb3677307305696bad5f069
https://pubmed.ncbi.nlm.nih.gov/10945624